Clinical-stage specialty pharmaceutical company Zynerba Pharmaceuticals (ZYNE) has received guidance from the U.S.
After passing one speed bump, is the market heading towards more bumps in the road? Following the September sell-off, there has been a …
Shares in Zynerba Pharma (ZYNE) jumped 6.4% in Thursday’s trading, and continued to climb 1.
To buy or not to buy, that’s the question. For even the most seasoned Wall Street observers, determining the ideal time to pull …
2019 has been a good year for the stock market. Year-to-date, both the S&P 500 and the Nasdaq are up 15% and 19%, …
The cannabis sector has seen tremendous amounts of excitement over the past few years. We have seen companies explode into billion-dollar valuations based …
The FDA has started looking into how it might legalize CBD-laced food products, and this is good news for Zynerba (ZYNE) investors. Today, …
The cannabis market is buzzing right now. But the recent rally in cannabis stocks has left some of the bigger names looking overvalued.
By Jimmy Butts I’ve avoided the topic and industry for a while now. But there’s no denying that it’s a burgeoning space with …
Canaccord analysts debating the impact of recent events on Zynerba and DexCom.
